Personalis (NASDAQ:PSNL) Trading 8.7% Higher – Here’s What Happened

Posted by Francis Steltz on May 28th, 2026

Shares of Personalis, Inc. (NASDAQ:PSNL – Get Free Report) traded up 8.7% on Thursday . The stock traded as high as $10.29 and last traded at $10.32. 1,043,793 shares were traded during trading, a decline of 40% from the average session volume of 1,726,333 shares. The stock had previously closed at $9.49.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. BTIG Research lowered their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Morgan Stanley lowered their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Finally, Needham & Company LLC boosted their price target on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Read Our Latest Report on Personalis

Personalis Price Performance

The company has a market capitalization of $1.10 billion, a PE ratio of -10.27 and a beta of 1.96. The stock’s 50 day simple moving average is $6.70 and its 200-day simple moving average is $8.05.

Personalis (NASDAQ:PSNL – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The business had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. On average, equities analysts predict that Personalis, Inc. will post -1.06 earnings per share for the current year.

Institutional Trading of Personalis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. increased its stake in Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after purchasing an additional 7,896,714 shares during the period. ARK Investment Management LLC grew its position in shares of Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after buying an additional 802,268 shares in the last quarter. Aberdeen Group plc grew its position in shares of Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after buying an additional 861,948 shares in the last quarter. Kennedy Capital Management LLC grew its position in shares of Personalis by 196.2% during the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after buying an additional 1,281,695 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Personalis by 1,332.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after buying an additional 1,347,439 shares in the last quarter. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

About Personalis

(Get Free Report)

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.